Researchers Identify a New Way to Determine Whether Metastatic Cancer Cells in Breast Cancer Patients are Dormant or Soon to Turn Deadly
Protein Can Be Used to Monitor Patients and Identify Drugs
For the first time ever, Mount Sinai researchers have identified a protein as a marker that can indicate whether a cancer patient will develop a reoccurrence of lethal, metastatic cancer, according to a clinical study published in Breast Cancer Research in October.
The researchers found that when cells from a breast cancer patient’s original tumor metastasized into the patient’s bone marrow with none, or only a small amount, of the protein NR2F1, the patients all soon died. However, patients who had a high concentration of NR2F1 in the cancer cells in their bone marrow did not frequently develop this type of metastatic cancer, and lived longer. The presence of a high concentration of NR2F1 induced dormancy in the cancer cells, essentially deactivating them, so this research shows that survival in these patients is due to the dormancy of the disseminated cancer.
These findings suggest that the absence of this protein in cancer cells that have spread to a patient’s bone marrow can reliably signal that the patient will relapse soon and that additional treatment is needed, while if the protein is present, the cancer cells are dormant and the patient can be monitored rather than undergo unnecessary treatment. This research is particularly important because the most common breast type of breast cancer, when it metastasizes, almost always goes to the bone.
The research is especially important in the United States because bone marrow tests, called aspirates, are not used to monitor patients there. The study was a collaboration with physicians and scientists in Oslo, Norway, where bone marrow aspirates are used to monitor patients. The laboratory of Bjorn Naume from University Hospital of Oslo collaborated with the Aguirre-Ghiso and Sosa labs at the Icahn School of Medicine at Mount Sinai and conducted the analysis of the patients’ samples from their clinical trials, thus contributing significantly to this research.
Using this research, physicians could monitor their patients with bone marrow aspirates. Tests for the protein could also help clinicians identify patients who may benefit from recently identified drugs that were shown to target cancer cells and render or keep them dormant. Studies have already shown that androgen deprivation treatment, an anti-hormone therapy used in prostate cancer, has been linked to increasing levels of the NR2F1 protein. Mount Sinai, through a trial funded by the V Foundation for Cancer Research and The Tisch Cancer Institute at the Icahn School of Medicine, has already begun recruiting prostate cancer patients for a test of the ability of two drugs to induce dormancy through NR2F1 upregulation.
“This research shows that the survival advantage in these patients is due to high levels of this protein. Tests using this protein marker could further improve curative treatment of breast cancer, sparing patients from unnecessary treatments. Identifying patients with disseminated disease that is not yet symptomatic and characterizing it for potential dormancy or metastatic recurrence is a game changer,” said lead researcher Julio Aguirre-Ghiso, PhD, Director of Solid Tumor and Metastasis Research, Director of Head and Neck Cancer Basic Research, and Professor of Oncological Sciences, Otolaryngology, and Medicine (Hematology and Medical Oncology) at The Tisch Cancer Institute at the Icahn School of Medicine. “Improved techniques to assess the population of patients with residual disease and their dormant or reactivating state will be key to identifying the risk of future metastasis despite undergoing standard treatment. This opens the way for testing new treatments that prevent metastasis by inducing dormancy or eradicating the dormant disseminated cancer cells that have not yet initiated metastatic growth.”
Funding was provided by the National Cancer Institute, the V Foundation for Cancer Research, The Tisch Cancer Institute, the Samuel Waxman Cancer Research Foundation, the Melanoma Research Alliance, and Susan G. Komen.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.